Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study
Journal of the International AIDS Society · 2024-02 · 27 (2)
DOI: 10.1002/jia2.26216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, online erschienen am 08.02.2024. Verfasst von Tinei Shamu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Newlands Clinic, Harare, Zimbabwe. Hauptthemen laut MEDLINE: HIV Infections, Hypertension, Anti-HIV Agents, Piperazines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAAA NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Dolutegravir (DTG) is widely used for antiretroviral therapy (ART). We compared weight and blood pressure trends and examined the association between high blood pressure and weight gain among people living with HIV (PLHIV) switching to or starting DTG‐based, efavirenz (EFV)‐based and ritonavir‐boosted atazanavir (ATV/r)‐based ART in Zimbabwe.
Methods
PLHIV aged 18 years or older who started or switched to DTG, EFV or ATV/r‐based ART between January 2004 and June 2022 at Newlands Clinic in Harare, Zimbabwe, were eligible. Weight was measured at all visits (Seca floor scales); blood pressure only at clinician‐led visits (Omron M2 sphygmomanometer). We used Bayesian additive models to estimate trends in weight gain and the proportion with high blood pressure (systolic >140 mmHg or diastolic >90 mmHg) in the first 2 years after starting or switching the regimen. Finally, we examined whether trends in the proportion with high blood pressure were related to weight change.
Results
We analysed 99,969 weight and 35,449 blood pressure records from 9487 adults (DTG: 4593; EFV: 3599; ATV/r: 1295). At 24 months after starting or switching to DTG, estimated median weight gains were 4.54 kg (90% credibility interval 3.88−5.28 kg) in women and 3.71 kg (3.07−4.45 kg) in men, around twice that observed for ATV/r and over four‐times the gain observed for EFV. Prevalence of high blood pressure among PLHIV receiving DTG‐based ART increased from around 5% at baseline to over 20% at 24 months, with no change in PLHIV receiving EFV‐ or ATV/r‐based ART. High blood pressure in PLHIV switching to DTG was associated with weight gain, with stronger increases in the proportion with high blood pressure for larger weight gains.
Conclusions
Among PLHIV starting ART or switching to a new regimen, DTG‐based ART was associated with larger weight gains and a substantial increase in the prevalence of high blood pressure. Routine weight and blood pressure measurement and interventions to lower blood pressure could benefit PLHIV on DTG‐based ART. Further studies are needed to elucidate the mechanisms and reversibility of these changes after discontinuation of DTG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Newlands Clinic, Harare, Zimbabwe.
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
- Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
- Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare, Zimbabwe.
ORCID-Profile: Tinei Shamu, Matthias Egger
Förderung
- NHLBI NIH HHS
- NIAAA NIH HHS
- NCI NIH HHS
- FIC NIH HHS
- NIDDK NIH HHS
- NIDA NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Shamu, T., Egger, M., Mudzviti, T., Chimbetete, C., Manasa, J., & Anderegg, N. (2024). Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study. Journal of the International AIDS Society, 27(2). https://doi.org/10.1002/jia2.26216
Vancouver
Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N. Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study. Journal of the International AIDS Society. 2024;27(2). doi:10.1002/jia2.26216
BibTeX
@article{Shamu2024,
author = {Shamu, Tinei and Egger, Matthias and Mudzviti, Tinashe and Chimbetete, Cleophas and Manasa, Justen and Anderegg, Nanina},
title = {Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study},
journal = {Journal of the International AIDS Society},
year = {2024},
volume = {27},
number = {2},
doi = {10.1002/jia2.26216}
}
EUVIMED